Eli Lilly and Company(LLY) - Stock detail

Eli Lilly and Company

US
LLY
Eli Lilly and Company(Listing date: 07/09/1970)

Eli Lilly and Company was incorporated in Indiana in 1901, with its predecessor being a pharmaceutical manufacturing enterprise founded by Colonel Eli Lilly in Indianapolis, Indiana in 1876. The company develops, manufactures and markets important pharmaceutical products. Its mission is to combine "Caring" and "Discovery" to create better lives for people around the world.

AI Trading DecisionBuy
Generated at:2026-03-04 16:41:56
Analysis based on Eli Lilly and Company financial performance data, technical indicators (RSI: 44.09/38.00, Williams %R: -86.49, Bollinger Bands), valuation metrics (trailing P/E: 47.85, dynamic P/E: 91.43), and market developments including EMA/FDA regulatory actions. Data covers recent financial performance, pipeline progress, and market conditions up to March 2026.
Summary

Eli Lilly and Company (LLY) demonstrates exceptional financial performance with 94.9% YoY net income growth and 44.7% revenue growth, justifying a Buy recommendation. Target price: $1,250 (24.5% upside from current price), stop-loss price: $950 (5.3% downside protection), confidence level: 0.75, risk score: 0.65 (Moderate-High Risk). Investment horizon: 3-6 months with recommended position sizing of 3-5% portfolio allocation.

Operation strategy
  • Investment Horizon: 3-6 months
  • Position Sizing: 3-5% portfolio allocation given volatility (ATR: $34.55)
  • Recommend stop-loss at $950 (5.3% downside) to protect against breakdown below key support
  • Key Monitoring Points: Q1 2026 earnings (April 2026), oral GLP-1 development progress, competitive moves by Novo Nordisk

Core Support

Reasoning summary
  • Fundamental Strength Justifies Premium Valuation: Eli Lilly demonstrates exceptional financial performance with 94.9% YoY net income growth and 44.7% revenue growth
  • Trailing P/E of 47.85 is high but reasonable given growth trajectory and margin expansion (net margin improved from 23.51% to 31.67%)
  • Profitability metrics are outstanding with ROE of 290.87% and ROA of 52.44%
  • Pipeline Diversification & Competitive Position: Recent positive developments include EMA approval for Olumiant in adolescent alopecia areata
  • Progress on oral GLP-1 candidate (orforglipron) and strong Phase 3b results for Taltz + Zepbound
  • $100+ billion GLP-1 market remains underpenetrated with room for multiple winners
  • FDA actions against compounded GLP-1 drugs actually strengthen Lilly's competitive position
  • Technical Oversold Condition: Current price ($1,003.57) represents a 9.4% pullback from recent highs, placing stock in oversold territory
  • Valuation-Based Target Price: Using trailing P/E of 47.85 and accounting for continued earnings growth momentum (20-25% projected), derive 3-month target of $1,150-$1,250